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ABSTRACT
Introduction Sex differences in cardiometabolic risk 
factors and their management in type 2 diabetes (T2D) 
have not been fully identified. Therefore, we aimed to 
examine differences in cardiometabolic risk factor levels, 
pharmacological treatment and achievement of risk factor 
control between women and men with T2D.
Research design and methods Cross- sectional data 
from the Dutch Diabetes Pearl cohort were used (n=6637, 
40% women). Linear and Poisson regression analyses 
were used to examine sex differences in cardiometabolic 
risk factor levels, treatment, and control.
Results Compared with men, women had a significantly 
higher body mass index (BMI) (mean difference 1.79 kg/
m2 (95% CI 1.49 to 2.08)), while no differences were found 
in hemoglobin A1c (HbA1c) and systolic blood pressure (SBP). 
Women had lower diastolic blood pressure (−1.94 mm Hg (95% 
CI −2.44 to −1.43)), higher total cholesterol (TC) (0.44 mmol/L 
(95% CI 0.38 to 0.51)), low- density lipoprotein cholesterol 
(LDL- c) (0.26 mmol/L (95% CI 0.22 to 0.31)), and high- density 
lipoprotein cholesterol (HDL- c) sex- standardized (0.02 mmol/L 
(95% CI 0.00 to 0.04)), and lower TC:HDL ratio (−0.29 (95% CI 
−0.36 to −0.23)) and triglycerides (geometric mean ratio 0.91 
(95% CI 0.85 to 0.98)). Women had a 16% higher probability of 
being treated with antihypertensive medication in the presence 
of high cardiovascular disease (CVD) risk and elevated SBP 
than men (relative risk 0.84 (95% CI 0.73 to 0.98)), whereas no 
sex differences were found for glucose- lowering medication 
and lipid- modifying medication. Among those treated, women 
were less likely to achieve treatment targets of HbA1c (0.92 
(95% CI 0.87 to 0.98)) and LDL- c (0.89 (95% CI 0.85 to 0.92)) 
than men, while no differences for SBP were found.
Conclusions In this Dutch T2D population, women had 
a slightly different cardiometabolic risk profile compared 
with men and a substantially higher BMI. Women had a 
higher probability of being treated with antihypertensive 
medication in the presence of high CVD risk and elevated 
SBP than men, and were less likely than men to achieve 
treatment targets for HbA1c and LDL levels.
INTRODUCTION
Sexual heterogeneity has emerged as a major 
topic in several medical areas, including 
metabolic disorders such as type 2 diabetes 
(T2D).1 A growing body of evidence shows 
that the relative risk (RR) of cardiovascular 
complications associated with T2D is different 
for women and men. In fact, T2D may atten-
uate the protective effect that female sex 
usually confers on the risk of cardiovascular 
disease (CVD).2–5 Meta- analyses have shown 
that the RR of coronary heart disease is up to 
Significance of this study
What is already known about this subject?
 ► There is a growing body of evidence that type 2 dia-
betes (T2D) is a stronger risk factor for cardiovascu-
lar complications in women than in men.
 ► We aimed to evaluate sex differences in the levels 
of cardiometabolic risk factors, pharmacological 
treatment and achievement of treatment targets for 
hemoglobin A
1c (HbA1c), systolic blood pressure (SBP) 
and low- density lipoprotein cholesterol (LDL- c), in a 
large, well- phenotyped cohort of Dutch individuals 
with T2D.
What are the new findings?
 ► Women, especially those with lower and middle 
educational levels, had a substantially higher body 
mass index than men, while other cardiometabolic 
risk factors were highly comparable.
 ► Women were more likely to receive antihypertensive 
medication in the presence of high cardiovascular 
disease risk and increased SBP, while no differences 
were found for glucose- lowering or lipid- lowering 
medication.
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50% higher in women with diabetes, compared with their 
male counterparts.6–8 For stroke, this RR is 27% greater 
in women with diabetes than in men.9 The reasons 
for these sex differences are likely multifactorial, for 
example physiological differences between women and 
men, including the impact of sex hormones,10–12 female- 
specific factors such as age of menarche, menopause, and 
childbearing history, oral contraception, and hormone 
replacement therapy13–15 and a more adverse cardiomet-
abolic risk profile among women than men with T2D.16 17 
In addition, healthcare provision for the prevention and 
delay of cardiovascular complications between men and 
women with diabetes may differ.13 15 17–21
Understanding of the sex differences in major modi-
fiable risk factors with respect to their quantity, treat-
ment and control in specific healthcare settings may 
help healthcare professionals to reduce these differ-
ences. In order to evaluate sex differences in the levels of 
cardiometabolic risk factors, pharmacological treatment 
and achievement of treatment targets for hemoglobin 
A1c (HbA1c), systolic blood pressure and low- density lipo-
protein cholesterol (LDL- c), in a large, well- phenotyped 
cohort of Dutch individuals with T2D, we used data 
from the Diabetes Pearl cohort. The Diabetes Pearl is a 
large Dutch cohort involving all eight academic medical 
centers in the Netherlands, covering different geograph-
ical areas, and has collected data from over 6500 indi-
viduals with T2D who are being treated in primary, 
secondary and tertiary care.22
RESEARCH DESIGN AND METHODS
Study population
Cross- sectional data from the Diabetes Pearl, an observa-
tional cohort study, involving all eight Dutch academic 
medical centers covering different geographical areas 
in the Netherlands, and covering individuals treated 
in primary, secondary and tertiary care, were used, as 
described in detail elsewhere.22 In short, individuals 
previously diagnosed with T2D who received secondary 
or tertiary medical care in one of the six academic 
medical centers in Amsterdam, Utrecht, Nijmegen, 
Rotterdam, Leiden or Groningen, primary medical 
care in the area of Hoorn, or who received primary, 
secondary or tertiary care in the region of Maastricht 
were eligible for participation.22 In 2018, an estimated 
1.2 million (47% women) individuals in the Nether-
lands had diabetes, with majority suffering from T2D 
(91%).23 Individuals with T2D are predominantly being 
treated in primary care (up to 85%). In the occurrence 
of complications of whenever glycemic control is not 
achieved by primary care, the patient will be referred 
to secondary care (ie, internal medicine, cardiology, 
ophthalmology, endocrinology). Only when high 
specialist care is needed, in complex cases, the patient 
is referred to tertiary care.22 Data were collected over 
a 6- year period (2009–2015) and included information 
on demographics, physical measurements, laboratory 
tests and questionnaires. Individuals were not included 
in the cohort if their ability to understand and write 
in Dutch language was too limited to provide written 
informed consent.22 A total of 6666 individuals diag-
nosed with T2D were included in the Diabetes Pearl. 
After excluding participants of whom sex was not known 
(missing), 6637 remained for analyses.
Measurements
Data on educational level (as a proxy for socioeconomic 
status), smoking behavior, alcohol consumption, history 
of diabetes, stroke, and CVD were obtained at baseline, 
using a self- report questionnaire. Information on sex and 
date of birth was obtained using the hospital information 
systems at all recruitment centers. Weight and height 
were measured barefoot and wearing light clothing using 
a clinical stadiometer and scale. Blood pressure was 
determined three times on the right arm after a 10 min 
rest period, using a non- invasive blood pressure monitor 
(Omron 7051 T in seven centers and Colin Press BP 
8800p in one center). Final blood pressure was calcu-
lated as the mean of the last two measurements. Fasting 
venous blood plasma was used to determine total choles-
terol (TC), high- density lipoprotein cholesterol (HDL- 
c), and triglycerides. A fasting whole blood sample was 
used to determine HbA1c level. All the laboratories were 
certified and located on- site in the eight clinics.22
Cardiometabolic profile
The following cardiometabolic risk factors were analyzed: 
systolic blood pressure (SBP), diastolic blood pressure 
(DBP), triglycerides, TC, HDL- c, LDL- c, TC:HDL ratio, 
body mass index (BMI), and HbA1c. Triglyceride levels 
were log- transformed due to non- normality and back- 
transformed to a geometric mean ratio. For HDL- c, 
specific cut- offs apply for women and men. Therefore, 
sex- standardized variables for HDL- c were used in the 
analyses of mean differences (MD) between women 
and men. Sex- standardized HDL- c was calculated as the 
observed value minus 1.2 mmol/L for women and the 
observed value minus 1.0 mmol/L for men.
Significance of this study
How might these results change the focus of research or 
clinical practice?
 ► Although sex differences in cardiovascular risk management among 
individuals with T2D are relatively small in the Netherlands, body 
mass index was almost two- point higher in women than in men, 
and more effective weight loss interventions are clearly needed.
 ► Furthermore, women had greater difficulty in attaining optimal 
HbA1c and LDL- c treatment targets despite pharmacological treat-
ment than men, and therefore future research should evaluate sex 
differences in adherence, drug type or dosage, and the underlying 
reasons for these differences in men and women with T2D.
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Pharmacological treatment and achievement of 
cardiometabolic risk factor targets
Information on medication use for the treatment of 
hyperglycemia, dyslipidemia and hypertension was 
collected either by asking participants to bring their medi-
cation on the day of visit to the clinic or by use of phar-
macy lists. Majority of individuals receiving treatment for 
hyperlipidemia (Anatomical Therapeutic Chemical Clas-
sification System C10) were treated with statins (95%). 
Treatment with other types of lipid- modifying medication 
(ie, fibrates) was limited. Although newer antidiabetic 
medication became available during the study period (ie, 
Glucagon- like peptide-1 (GLP1) analogs and Sodium- 
glucose cotransporter-2 (SGLT2) inhibitors in 2009 and 
2011, respectively), these were not yet prescribed to 
our study population. Pharmacological management of 
hyperglycemia, dyslipidemia and hypertension was each 
categorized into four groups, based on the individual’s 
medication use, the levels of SBP, LDL- c and HbA1c at 
target (ie, below or above cut- off), and the individual’s 
estimated 10- year CVD risk (online supplemental table 
1):
 ► No treatment and no treatment indication: not 
receiving glucose- lowering medication and HbA1c 
≤53 mmol/mol; not receiving antihypertensive medi-
cation and SBP ≤140 mm Hg, or SBP >140 mm Hg with 
Table 1 Study population characteristics stratified by sex
Men,
n=3969 (60%)
Women, 
n=2668 (40%)
Age, years 62.7±9.6 61.8±11.1
Diabetes duration, 
years
9.1 (4.3–15.1) 9.0 (4.4–15.1)
Educational level*
  Low 1169 (32) 1066 (43)
  Moderate 1558 (42) 1065 (43)
  High 968 (26) 335 (14)
Smoking status
  Never 935 (27) 1111 (46)
  Former 1904 (54) 925 (39)
  Current 690 (20) 360 (15)
Alcohol use†
  No 1241 (33) 1484 (60)
  Low 1987 (53) 738 (30)
  High 516 (14) 248 (10)
Prior CVD 1420 (40) 673 (30)
10- year CVD risk
  Low risk 108 (3) 288 (12)
  Intermediate risk 187 (5) 336 (14)
  High risk 3271 (92) 1759 (74)
Healthcare setting
  Primary care 2238 (57) 1489 (56)
  Secondary/tertiary 
care
1701 (43) 1154 (44)
Cardiometabolic factors
Systolic blood 
pressure, mm Hg
142.6±18.9 141.3±20.1
Diastolic blood 
pressure, mm Hg
78.6±10.4 76.7±10.0
Triglycerides, mmol/L 1.6 (1.1–2.3) 1.5 (1.1–2.1)
Total cholesterol, 
mmol/L
4.28±1.12 4.73±1.39
HDL- c, mmol/L 1.14±0.32 1.36±0.39
LDL- c, mmol/L 2.3±0.8 2.6±1.0
Cholesterol ratio 
(total:HDL)
3.97±1.42 3.69±1.27
Weight, kg 94.2±17.9 85.5±18.8
Height, cm 177±7 164±7
Body mass index,
kg/m2
30.0±5.2 31.9±6.7
Waist circumference, 
cm
108.4±13.6 104.5±15.6
HbA1c, mmol/mol 55.0±13.6 55.4±14.2
Medication use
Diabetes medication
  None 538 (14) 403 (16)
Continued
Men,
n=3969 (60%)
Women, 
n=2668 (40%)
  Oral only 1769 (46) 1097 (42)
  Insulin and oral 1053 (27) 690 (27)
  Insulin only 518 (13) 401 (16)
Lipid- modifying 
medication
2740 (71) 1628 (63)
Antihypertensive 
medication
2688 (69) 1807 (70)
Antithrombotic 
medication
1689 (44) 802 (31)
Data are presented as mean±SD or median (IQR) where 
appropriate for continuous variables and n (%) for 
categorized variables.
Due to missing data not all variables add up to n=2668 for 
women and n=3969 for men.
*Low education includes no education, primary school not 
finished, primary education, and low vocational education. 
Moderate education includes intermediate vocational 
education, high secondary education, and high vocational 
education. High education includes high professional 
education and university education.
†Alcohol use was divided into three categories: none: no 
alcohol use; low: ≤7 glasses per week for women and ≤14 
glasses per week for men; high: >7 glasses per week for 
women and >14 glasses per week for men.
CVD, cardiovascular disease; HbA1c, hemoglobin A1c; 
HDL- c, high- density lipoprotein cholesterol; LDL- c, low- 
density lipoprotein cholesterol.
Table 1 Continued
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low or intermediate 10- year CVD risk; not receiving 
lipid- modifying medication and LDL- c ≤2.5 mmol/L, 
or >LDL- c 2.5 mmol/L with low or intermediate 
10- year CVD risk.
 ► Optimal treatment: receiving glucose- lowering medi-
cation and HbA1c ≤53 mmol/mol; receiving antihyper-
tensive medication and SBP ≤140 mm Hg; receiving 
lipid- modifying medication and LDL- c ≤2.5 mmol/L.
 ► Suboptimal treatment: receiving glucose- lowering 
medication and HbA1c >53 mmol/mol; receiving 
antihypertensive medication and SBP >140 mm Hg; 
receiving lipid- modifying medication and LDL- c 
>2.5 mmol/L.
 ► No treatment despite a treatment indication: not 
receiving glucose- lowering medication despite HbA1c 
>53 mmol/mol; not receiving antihypertensive medi-
cation despite high CVD risk and SBP >140 mm Hg; 
not receiving lipid- modifying medication despite 
high CVD risk and LDL- c >2.5 mmol/L.
The individual’s 10- year risk of CVD was estimated 
by use of an adapted version of the SCORE risk model. 
Estimation of the 10- year CVD risk was based on sex, age 
(biological age +15 years to compensate for the increased 
CVD risk associated with T2D as recommended by the 
adapted version of the SCORE risk model according to 
Dutch guidelines), current smoking, SBP and TC:HDL 
ratio, and classified as low (<10%), intermediate (10%–
20%) or high (>20% or prevalent CVD).24
Statistical analysis
Population characteristics were described, by sex, as 
mean±SD or median (IQR) where appropriate for 
continuous variables and n (%) for categorized variables. 
Information on missing data can be found in online 
supplemental table 2.
Age and medication- adjusted linear regression analyses 
were performed to study sex differences in cardiometa-
bolic risk factor levels. Linear regression analyses on 
HbA1c were adjusted for glucose- lowering medication; 
analyses on the lipid spectrum were adjusted for lipid- 
modifying medication; and analyses on blood pressure 
were adjusted for antihypertensive medication.
Age- adjusted Poisson regression analyses25 with robust 
SEs were used to obtain RR with 95% CI for sex differ-
ences in the treatment and achievement of cardiometa-
bolic risk factor targets (HbA1c, SBP, and LDL- c).
Given that the data used for this study were collected 
over a 6- year period and guidelines have changed over 
time, we additionally analyzed treatment based on risk 
factor levels irrespective of 10- year estimated CVD risk. 
Secondary interaction analyses on history of CVD (yes 
vs no), healthcare setting (primary care vs secondary 
care and tertiary care), age (<60 years vs ≥60 years), 
BMI (<25 kg/m2 vs ≥25 kg/m2), and educational level 
(low, middle, high) were performed. We decided to only 
adjust our analyses for age as other variables such as BMI 
are thought to be mediating factors, and our goal was to 
examine the independent effects of sex on treatment and 
achievement of risk factor targets.
Statistical analyses were performed using SPSS V.25.0 
for Windows.
RESULTS
Data from 6637 individuals (40% women), with a mean 
age of 62 years and a median T2D duration of 9 years, 
were used. On average, men were more likely than 
women to smoke, drink alcohol, have a known history 
of CVD, have a high 10- year CVD risk, and to use lipid- 
modifying medication. Women had higher TC, LDL- c 
and HDL- c levels and higher BMI than men (table 1).
Cardiometabolic risk factor levels
Figure 1 shows the sex- specific cardiometabolic risk 
factor levels and age- adjusted associations between 
sex and cardiometabolic risk factor levels. Results are 
expressed as MD and 95% CI. Compared with men, 
women had a higher BMI (MD 1.79 kg/m2 (95% CI 1.49 
to 2.08)) and similar levels of HbA1c (MD 0.32 mmol/
mol (95% CI −0.37 to 1.00)) and SBP (MD −0.86 mm Hg 
(95% CI −1.80 to 0.09)). Furthermore, women had lower 
DBP (MD −1.94 mm Hg (95% CI −2.44 to −1.43)), higher 
TC (MD 0.44 mmol/L (95% CI 0.38 to 0.51)), LDL- c 
(MD 0.26 mmol/L (95% CI 0.22 to 0.31)), and HDL- c- 
standardized (MD 0.02 mmol/L (95% CI 0.00 to 0.04)), 
and lower TC:HDL ratio (MD −0.29 (95% CI −0.36 to 
−0.23)) and triglycerides (geometric mean ratio 0.91 
(95% CI 0.85 to 0.98)) than men. Results did not change 
after additional adjustments for medication use (results 
not shown).
Figure 1 Age- adjusted women- to- men mean differences of 
cardiometabolic risk factor levels. A mean difference in BMI 
of 1.79 kg/m2 means that the age- adjusted BMI in women is 
1.79 kg/m2 higher than in men. Back transformation of log- 
transformed triglycerides results in a geometric mean ratio of 
0.91 (95% CI 0.85 to 0.98). Men: reference. BMI, body mass 
index; DBP, diastolic blood pressure; HbA1c, hemoglobin 
A1c; HDL- c, high- density lipoprotein cholesterol; LDL- c, low- 
density lipoprotein cholesterol; SBP, systolic blood pressure; 
TC, total cholesterol.
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Pharmacological treatment of cardiometabolic risk factors
Figure 2 shows the pharmacological treatment of hyper-
glycemia, hypertension and dyslipidemia, among those 
without relevant missing data. Overall, 84%, 71% and 64% 
of women and 86%, 71% and 72% of men with known 
risk factor levels were treated with glucose- lowering, 
blood pressure- lowering or lipid- modifying medication, 
respectively.
Compared with men, women had a 16% higher prob-
ability of being treated with antihypertensive medica-
tion in the presence of high CVD risk and elevated SBP 
(RR 0.84 (95% CI 0.73 to 0.98)), whereas no statistically 
Figure 2 Pharmacological treatment and achievement of treatment targets of hyperglycemia (upper panel), hypertension 
(middle panel) and dyslipidemia (lower panel) in percentages for women and men. No treatment and no indication: no 
medication use and no indication for treatment (risk factor below cut- off or either low or medium 10- year CVD risk in case 
of SBP >140 mm Hg or LDL- c >2.5 mmol/L); optimal treatment: medication use and risk factor below cut- off; suboptimal 
treatment: medication use and risk factor above cut- off; no treatment despite indication: no medication use, but HbA1c>53 
mmol/mol or high 10- year CVD risk and SBP >140 mm Hg or LDL- c >2.5 mmol/L. CVD, cardiovascular disease; HbA1c, 
hemoglobin A1c; LDL- c, low- density lipoprotein cholesterol; SBP, systolic blood pressure.
Figure 3 Age- adjusted women to men risk ratios with 95% CI for treatment of cardiometabolic risk factors according to risk 
factor levels and 10- year CVD risk score. Men and women refer to the total number of participants included in the analyses, 
and % refers to the number of participants not receiving glucose- lowering, antihypertensive or lipid- modifying medication. 
Men: reference. CVD, cardiovascular disease; HbA1c; hemoglobin A1c; LDL- c, low- density lipoprotein cholesterol; SBP, systolic 
blood pressure.
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significant sex difference was found for being treated 
with antihypertensive medication in the presence of 
elevated SBP irrespective of high CVD risk (RR 0.91 
(95% CI 0.80 to 1.02)). No sex differences were found for 
glucose- lowering medication in the presence of elevated 
HbA1c levels (RR 0.98 (95% CI 0.67 to 1.45)), and lipid- 
modifying medication in the presence of elevated LDL- c 
levels and high CVD risk (RR 1.06 (95% CI 0.97 to 1.16)) 
and irrespective of CVD risk (RR 1.07 (95% CI 0.99 to 
1.15)) (figure 3).
Achievement of treatment targets
Among those treated with glucose- lowering medication, 
blood pressure- lowering medication or lipid- modifying 
medication, 45%, 45% and 69% of women and 50%, 44% 
and 78% of men achieved targets of HbA1c (≤53 mmol/
mol), SBP (≤140 mm Hg) or LDL- c (≤2.5 mol/L), respec-
tively. After adjustment for age, women were less likely to 
achieve risk factor targets of HbA1c (RR 0.92 (95% CI 0.87 
to 0.98)) and LDL- c (RR 0.89 (95% CI 0.85 to 0.92)) than 
men, while no sex differences were found for control of 
SBP (RR 1.03 (95% CI 0.96 to 1.10)).
Subgroup and interaction analyses
Results from the interaction analyses on history of CVD, 
healthcare setting (primary, secondary and tertiary care), 
age, BMI and educational level are summarized in online 
supplemental tables 3 and 4.
For cardiometabolic risk factors, the interaction anal-
yses by history of CVD, healthcare setting, age, BMI and 
educational level showed several significant interactions, 
but most differences were very small and unlikely to be 
clinically relevant (online supplemental table 3), with 
two exceptions. First, women with high educational level 
had lower SBP (MD −4.34 (95% CI −6.89 to −1.80)) than 
men, compared with lower educational levels (p=0.046). 
Second, women with low and middle educational levels 
had higher BMI compared with their male counterparts 
(MD 2.13 (95% CI 1.58 to 2.67) and MD 1.29 (95% CI 
0.80 to 1.78), respectively), while no statistically signifi-
cant sex differences were found for high educational 
level (MD 0.49 (95% CI −0.22 to 1.20)) (p<0.001).
Women with a history of CVD had a higher likelihood 
of not receiving lipid- modifying medication despite high 
CVD risk and elevated LDL- c than men (RR 1.26 (95% 
CI 1.03 to 1.53)), while no such sex difference was found 
for participants without CVD (RR 0.94 (95% CI 0.83 to 
1.05)). Similar results for not receiving lipid- modifying 
medication in the presence of elevated LDL- c were found 
irrespective of high CVD risk. Women in primary care 
had a lower likelihood of not receiving antihyperten-
sive medication despite high CVD risk and elevated SBP 
than men (RR 0.73 (95% CI 0.61 to 0.88)) in contrast to 
secondary or tertiary care (RR 1.12 (95% CI 0.85 to 1.49)), 
and women in secondary or tertiary care had a higher 
likelihood of not receiving lipid- modifying medication 
despite high CVD risk and elevated LDL- c than men (RR 
1.28 (95% CI 1.08 to 1.53)) (online supplemental table 
4). Women with higher educational level had a higher 
likelihood of not receiving antihypertensive medication 
despite elevated SBP and high CVD risk than men (RR 
1.27 (95% CI 0.92 to 1.76)), while women with lower 
educational levels were more likely to receive antihy-
pertensive medication (RR 0.74 (95% CI 0.56 to 0.97). 
Similar results for not receiving antihypertensive or lipid- 
modifying medication were found, irrespective of high 
CVD risk.
With regard to achievement of treatment targets, 
women in secondary or tertiary care were less likely to 
attain HbA1c ≤53 mmol/mol than men when receiving 
glucose- lowering medication (0.80 (95% CI 0.71 to 
0.90)), while no such sex difference was found for partic-
ipants in primary care (0.96 (95% CI 0.89 to 1.03)) 
(online supplemental table 4). Moreover, women with 
higher educational levels were more likely to attain SBP 
≤140 mm Hg than men, when receiving antihypertensive 
medication (1.34 (95% CI 1.13 to 1.58)).
DISCUSSION
Data from the Dutch Diabetes Pearl show that sex dispar-
ities in cardiometabolic risk factor levels, pharmaco-
logical treatment and achievement of cardiometabolic 
risk factor control exist, with three major findings. (1) 
Women, especially those with lower and middle educa-
tional levels, had a substantially higher BMI than men, 
while other cardiometabolic risk factors were highly 
comparable, although statistically significantly different 
for DBP and markers of dyslipidemia. (2) Women were 
more likely to receive antihypertensive medication in 
the presence of high CVD risk and increased SBP, while 
no differences were found for treatment with glucose- 
lowering medication or lipid- modifying medication. (3) 
Proportions of men and women who did not achieve 
optimal treatments targets for glucose blood pressure 
and lipids, despite their treatment, were large, ranging 
from 22% to 56%, and women were less likely to achieve 
treatment targets of HbA1c and LDL- c, while receiving 
glucose- lowering and lipid- modifying medication.
Cardiometabolic risk factor levels
In women with T2D, BMI was 1.79 kg/m2 higher than 
in men with T2D, which is in line with several previous 
studies conducted in various countries, including the 
Netherlands, Spain, Italy, and the UK, and more effective 
weight loss interventions are clearly needed.26–29 It has 
been hypothesized that cardiometabolic risk factors need 
to deteriorate further in women than men before they 
develop overt T2D.2 16 18 30 31 As a consequence, women 
may be exposed to hazardous cardiometabolic risk factors 
for a longer period of time, which may increase their CVD 
risk. Sex differences in the metabolism and the storage 
of fat may be of particular interest, and several studies 
have shown that fat storage and distribution differ by sex, 
with women having a greater subcutaneous fat storage, 
while on average men have greater visceral and ectopic 
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fat storages.15 18 Visceral and ectopic fat have been linked 
to insulin resistance. As a consequence, compared with 
men, women may need to gain more weight to store 
visceral and ectopic fat before developing insulin resis-
tance and overt T2D. Thus, women may be exposed to 
hazardous cardiometabolic risk factors for an extended 
period of time before they are diagnosed with T2D and 
receive treatment.2 16 18 30 31
Treatment of cardiometabolic risk factors
Proportions of both men and women who did not 
receive antihypertensive or lipid- modifying treatment, 
despite high CVD risk and SBP >140 mm Hg or LDL- c 
>2.5 mmol/L, were substantial, ranging from ~20% for 
hypertension to ~50% for dyslipidemia, and women 
were more likely to receive antihypertensive treatment 
than men in the presence of high CVD risk and SBP 
>140 mm Hg. These results are comparable with those of 
a Dutch primary care study, which found that 16% and 
48% of those with a treatment indication did not receive 
prescriptions for antihypertensive and lipid- modifying 
medication, respectively.27 Based on our data we cannot 
assess the ground for this suboptimal CVD risk factor 
treatment. However, a focus on antihyperglycemic treat-
ment rather than the treatment of hypertension or on 
individualized care with personalized treatment targets 
could play a role. Furthermore, patients may be reluctant 
to start certain medications, that is, statins, due to fear of 
side effects.
Control of cardiometabolic risk factor levels
Women with T2D receiving glucose- lowering or lipid- 
modifying medication were, respectively, 8% (RR 0.92 
(95% CI 0.87 to 0.98)) and 11% (RR 0.89 (95% CI 0.85 
to 0.92)) less likely to attain treatment targets than men, 
while no differences were found for antihypertensive 
treatment. Other studies on sex differences in achieving 
HbA1c targets have reported mixed findings. In agree-
ment with our findings, some other studies found that 
women were less likely to attain HbA1c targets,17 28 32 while 
others did not.26 27 A recent study including 53 602 Dutch 
individuals with pharmacologically treated T2D found 
no clear sex differences in goal attainment of HbA1c and 
SBP, while women were less likely to attain LDL- c control 
compared with men.33 A higher BMI of women with T2D, 
presumably with higher insulin resistance, could explain 
the lower attainment of HbA1c targets in our study. The 
finding of worse LDL- c control among women with T2D 
is consistent with previous studies which showed an OR 
of up to 44%.17 26–28 32 Possible explanations include a 
differential biological response to lipid- modifying medi-
cation, or sex differences in dosage, type of medication, 
medication tolerance or adherence. In the general popu-
lation, several studies have shown the adherence to blood 
pressure- lowering and lipid- lowering medication to be 
lower in women than in men.34–36 To our knowledge, 
such studies have not yet been conducted in individuals 
with T2D. Furthermore, a recently published systematic 
review studying the participation of women in 740 cardio-
vascular clinical trials with 862 652 participants showed 
that, although this has improved over the last decade, 
men still predominate majority of cardiovascular clin-
ical trials.37 Reporting sex- specific results from clinical 
trials is important to obtain more insight into potential 
sex differences of treatment benefit and medication 
tolerance. Therefore, novel approaches to the recruit-
ment and enrollment process and novel trial designs are 
needed to ensure that sex- specific results may be mean-
ingfully obtained and applied to clinical practice.37
Another possible explanation may be found in differ-
ences of cardiometabolic risk factor levels at treatment 
initiation. As discussed earlier, it has been hypothesized 
that cardiometabolic risk factors need to deteriorate 
further in women than men before they are diagnosed 
with overt T2D. Therefore, it may take more aggressive 
treatment strategies to lower cardiometabolic risk factor 
levels in women compared with men.
Sex-specific risk factors
Certain factors that may impact cardiovascular risk are 
unique to women, including higher levels of female 
hormones, age of menarche, age of menopause and use 
of oral contraceptive and hormonal therapy. Studying the 
impact of sex hormones on the development of cardio-
vascular complications is challenging, especially given 
the cyclic fluctuations in hormone levels among women. 
However, we did not find evidence in the magnitude of 
sex differences among younger and older (as proxy for 
menopausal status) participants in subgroup analyses. 
Previous studies have found several female reproductive 
factors, including childbearing history, age at menarche, 
and age at menopause, to be associated with adiposity,38 39 
thereby suggesting that female reproductive factors may 
be involved in the development of T2D and cardiovas-
cular complications.13 Future studies are needed to 
further investigate the direct impact of sex hormones on 
the onset of CVD.
Clinical implications
The development of diabetes and cardiovascular compli-
cations is a process of decades. As mentioned before, it 
has been hypothesized that women may be exposed to a 
hazardous cardiovascular environment for a longer period 
than men before the onset of diabetes. This hypothesis is 
supported by a study showing that, on average, men have 
pre- diabetes for 8 years and women for 10 years.40 This 
time window may offer clinicians the opportunity to iden-
tify those at increased risk for diabetes and subsequently 
offer the opportunity for timely intervention.31
As cardiovascular risk factor levels seem to deteriorate 
more strongly in women than in men, before the onset of 
diabetes,16 it is of great importance to conduct a thorough 
cardiovascular risk assessment in women at risk of diabetes 
and those with overt diabetes, while not neglecting men.31 
Moreover, increasing awareness among physicians about 
the stronger deterioration of risk factors in women is 
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recommended to prevent women with diabetes from being 
treated less aggressively than men.31
Finally, this study showed that both men and women 
with T2D had high BMI levels, with women having a 
considerably higher BMI than men. These results are in 
accordance with previous literature, and effective weight 
loss strategies seem urgently needed with better facilita-
tion of lifestyle changes.31
Strengths and limitations
This large cohort included individuals with T2D 
receiving primary, secondary, and tertiary care in one of 
eight medical centers across the Netherlands covering 
different geographical areas, and thereby provides a 
well- phenotyped cohort of Dutch individuals with T2D. 
Nevertheless, our study also has limitations.
Data were collected over a 6- year period (2009–2015).22 
Given the rapid change of guidelines for the treatment 
of diabetes, some of our results may be less generaliz-
able to current clinical practice. Nevertheless, the main 
aim of our study was to investigate sex differences in the 
management of diabetes. Since most of the evidence- 
based guidelines provide similar recommendations for 
both sexes and no sex- specific recommendations were 
published over time, valid conclusions about sex differ-
ences can be drawn from the available data that were 
used for this study. Guidelines on diabetes care increas-
ingly focus on individualized care. Therefore, the more 
general treatment targets used in this study may have 
limited the generalizability of the findings to clinical 
practice. Moreover, a strict definition of CVD risk was 
used in this study without taking risk- enhancing factors, 
that is, family history of CVD, into account.24 As a result, 
the proportion of individuals with a treatment indica-
tion at baseline might be underestimated. Although we 
do not expect substantial differences in risk- enhancing 
factors between women and men, the proportions of 
women and men with an intermediate CVD risk did 
differ (14% vs 5%, respectively), which might have led 
to more misclassified women than men. As a result, sex 
differences might be underestimated or overestimated.
Furthermore, individuals were indicated to receive 
lipid- modifying medication in case of a high 10- year CVD 
risk combined with LDL- c level >2.5 mmol/L. This cut- off 
value was adopted from the Dutch guideline cardiovas-
cular risk management, which is used in primary care.24 
In secondary and tertiary care, physicians often use a cut- 
off value of >1.8 mmol/L when patients have a history of 
CVD, which means that we have been less strict than in 
clinical practice.
Finally, in this study we examined sex differences in the 
management of diabetes using a cross- sectional design. 
However, the management of diabetes and the preven-
tion and delay of diabetes complications are an ongoing 
dynamic process. For example, optimal treatment was 
defined as achievement of prespecified treatment targets 
according to current guidelines, while in reality the 
absolute drop in cardiovascular levels from the start of 
treatment may be more important. Also, medication use 
and risk factor levels are obtained at the same time, while 
setting the right treatment regimen takes time. Unfortu-
nately, due to the cross- sectional design, we do not have 
the information to take the dynamics of this process 
into account. This requires further investigation, ideally 
in studies with repeated risk factor measurements and 
longitudinal follow- up of pharmacological interventions.
CONCLUSION
In summary, in this population of Dutch individuals with 
T2D from primary, secondary and tertiary care, women 
had a considerably higher BMI than men and a greater 
difficulty in attaining HbA1c and LDL- c treatment targets, 
while men were less likely to receive antihypertensive 
medication despite high CVD risk and elevated SBP. 
Effective weight loss strategies seem urgently needed.
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